Multimodal MRI in Multiple Sclerosis (MS): Reliability and Follow Up

This study is ongoing, but not recruiting participants.
Institut National de la Santé Et de la Recherche Médicale, France
Information provided by:
Groupe Hospitalier Pitie-Salpetriere Identifier:
First received: February 8, 2006
Last updated: NA
Last verified: September 2005
History: No changes posted
To determine wether multimodal MRI (conventinal T1 and T2 sequences, diffusion, magnetization transfer, spectroscopy) is reproducible; to follow up a cohort of patients with early remmittent MS after treatment with interferon.

Condition Phase
Multiple Sclerosis
Phase 4

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Follow Up by Multimodal MRI of a Cohort of Patients With Early Remitting Multiple Sclerosis (REPROMMS Study).

Resource links provided by NLM:

Further study details as provided by Groupe Hospitalier Pitie-Salpetriere:


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MS patients according to Poser's criteria
  • Remitting evolution (less than two years of evolution)
  • Aged 18-50
  • Immunomodulatory treatment indicated

Exclusion Criteria:

  • Unable to perform MRI
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00289159

Sponsors and Collaborators
Groupe Hospitalier Pitie-Salpetriere
Institut National de la Santé Et de la Recherche Médicale, France
Principal Investigator: Ayman Tourbah, MD, PhD Assistance Publique - Hôpitaux de Paris
  More Information Identifier: NCT00289159     History of Changes
Other Study ID Numbers: RBM0110 
Study First Received: February 8, 2006
Last Updated: February 8, 2006

Keywords provided by Groupe Hospitalier Pitie-Salpetriere:
aged 18-50
remitting evolution
less than two years of evolution
MS patients

Additional relevant MeSH terms:
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases processed this record on January 19, 2017